No Detail Found!

Effect of nebivolol beneficial on lipid profile and glycemic control in comparison with Atenolol in patients with type 2 DM with concomitant hypertension

Author(s)
Abdul Majid Department of Cardiology Sheikh Zayed Medical College/Hospital Rahim Yar Khan,Punjab,Pakistan
Amir Javed Department of Cardiology Sheikh Zayed Medical College/Hospital Rahim Yar Khan,Punjab,Pakistan
Mazhar Hussain Department of Pharmacology& Therapeutics Sheikh Zayed Medical College/Hospital Rahim Yar Khan,Punjab,Pakistan
Zeeshan Faisal Department of Cardiology Sheikh Zayed Medical College/Hospital Rahim Yar Khan,Punjab,Pakistan
Asim Elahi Department of Internal Medicine CHI Saint Joseph Hospital,London, Kentucky,USA
Lubna Akhtar Department of Pharmacology& Therapeutics Sheikh Zayed Medical College/Hospital Rahim Yar Khan,Punjab,Pakistan
Abstract
Blood pressure control in hypertensive patients with metabolic abnormalities is challenging because many antihypertensive drugs adversely affect metabolism. Nebivolol a 3rd generation vasodilatory ß-blocker offer neutral or beneficial effects on insulin sensitivity and lipid metabolism. The purpose of this study was to evaluate the effect of nebivolol and atenolol on glycemic control and lipid profile in type 2 diabetes patients with concomitant hypertension. We conducted a 12 weeks double blind randomized clinical trial at Sheik Zayed Hospital Rahim Yar Khan. Patients were randomly divided in to two groups. Patients in group were given tablet nebivolol 5-10mg while patients in group B were given tablet Atenolol 25-50mg/daily for a period of 12 weeks. Pre and post data were analyzed by SPSS 20. After 12 weeks, Both drugs lowered blood pressure significantly i.e. nebivolol (SBP from152±12 to130±14 with p=0.004, DBP from 95±12 to78±8.5 with p=0.002) Atenolol (SBP from148±16.5 to 128±15.5 with p=0.006, DBP from 90±10.5 to 82±12 with p=0.003).Similarly both Nebivolol and Atenolol did not any significant effect on glycemic control and lipid profile at 12 week with in groups. However when comparison was done between two groups, Nebivolol significantly reduced blood sugar (p?0.001), HbA1c (p=0.0032), total Cholesterol (p=0.002), triglycerides (p=0.012), LDLCholesterol (p=0.007) and HDL-Cholesterol (p=0.001) as compared to atenolol. In comparison with atenolol, Nebivolol has a beneficial effect on glycemic control and serum lipid profile.
Publication Details
Page(s) 1891-1895
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: SUP5, Year: 2021

Request the full text from PASTIC

Keywords
Hypertension, blood sugar, Atenolol, Lipid Profile, nebivolol, lipid profile
References
Arazi H and Gonzalez M .2017 .Nebivolol: Does the key lie in β3 agonism. Clin. Surg., 2(6) : 1660.
Badar VA,Hiware SK,Shrivastava MP,Thawani VR,Hardas MM .2011 .Comparison of nebivolol and atenolol on blood pressure, blood sugar and lipid profile in patients of essential hypertension. Indian J. Pharmacol., 43(4) : 437.
Bhosale VV,Inamdar SC,Karande VB,Burute SR,Murthy MB,Ghatak A .2014 .Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J. Clin. Diagn., Res, 8(6) : HC01-04.
Chung J,Han JK,Kim YJ,Kim CJ,Ahn Y,Chan Cho M,Chae SC,Chae IH,Chae JK,Seong IW,Yang HM .2017 .Benefit of Vasodilating β‐Blockers in Patients with acute myocardial infarction after percutaneous coronary intervention: nationwide multicenter cohort study. J. Am. Heart Assoc., 6(10) : e007063.
Coats A,Jain S A .2017 .Protective effects of nebivolol from oxidative stress to prevent hypertension-related target organ damage. J. Hum. Hypertens., 31(6) : 376-381.
Tsimihodimos V,Gonzalez-Villalpando C,Meigs JB,Ferrannini E .2018 .Hypertension and diabetes mellitus: Coprediction and time trajectories. Hypertension, 71(3) : 422-428.
do Vale GT,Ceron CS,Gonzaga NA,Simplicio JA,Padovan JC .2019 .Three generations of β-blockers: history, class differences and clinical applicability. Curr. Hypertens. Reviews, 15(1) : 22-31.
Kwon SW,Do JY,Hong GR,Kim BK,Hwang WM,Kim SH,Lee JY,Park SW,Kim DH,Benefit-Korea DH .2018 .P1871 Effect of nebivolol on lipid and metabolic profiles in Korean patients with hypertension: Result from Benefit-Korea study. Eur. Heart J., 39(Suppl 1) : ehy565-P1871.
Liu JY,Guo LN,Peng WZ,Jiang Y,Wang AL,Guo XM,Xu ZS .2020 .Efficacy and safety of nebivolol in hypertensive patients: A meta-analysis of randomized controlled trials. J. Int. Med. Res., 48(10) : 10.
Marketou M,Gupta Y,Jain S,Vardas P .2017 .Differential metabolic effects of beta-blockers: An updated systematic review of nebivolol. Curr. Hypertens. Rep, 19(3) : 22.
Marketou M,Gupta Y,Jain S,Vardas P .2017 .Differential metabolic effects of beta-blockers: An updated systematic review of nebivolol. Curr. Hypertens. Rep, 19(3) : 22.
Merugu PL,Bingi TC .2020 .Effect of nebivolol on microalbuminuria in hypertensive patients with or without type 2 diabetes mellitus. J. Pharmacol. Pharmacother., 11(1) : 13-18.
Olawi N,Krüger M,Grimm D,Infanger M,Wehland M M .2019 .Nebivolol in the treatment of arterial hypertension. Basic Clinical Pharmacol. Toxicol., 125(3) : 189-201.
Ozyıldız AG,Eroglu S,Bal U,Atar I,Okyay K,Muderrisoglu H K .2017 .Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J. Cardiovasc. Pharmacol. Ther., 22(1) : 65-70.
Petrie JR,Guzik TJ,Touyz RM .2018 .Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J. Cardiol., 34(5) : 575-584.
Saeedi P,Petersohn I,Salpea P,Malanda B,Karuranga S,Unwin N,Colagiuri S,Motala L,Ogurtsova AA,Shaw K,JE K .2019 .Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Prac, 157 : 107843.
Schmidt AC,Graf C,Scholze J .2007 .Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. Clin. Drug Investig, 27(12) : 841-849.
Unge T,Borghi C,Charchar F,Khan NA,Poulter NR,Prabhakaran D,Ramirez A,Schlaich M,Stergiou GS,Tomaszewski M,Wainford RD M .2020 .. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension, 75(6) : 1334-1357.
Van Bortel LM .2010 .Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: A post-marketing surveillance study. Eur. Rev Med Pharmacol. Sci., 14(9) : 749-758.
Walczak-Gałęzewska M,Szulińska M,Miller-Kasprzak E,Pupek-Musialik D,Bogdański P .2018 .The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial. Medicine, 97(30) : 10.
Zheng Y,Ley SH,Hu FB .2018 .Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol., 14(2) : 88.
0

Citations

0

Downloads

10

Views